Effects of Cetuximab Combined with Celecoxib on Apoptosis and KDR and AQP1 Expression in Lung Cancer
10.3779/j.issn.1009-3419.2013.12.02
- VernacularTitle:西妥昔单抗联合塞来昔布对肺腺癌细胞KDR和AQP1表达的影响
- Author:
XIA HONGGANG
1
,
2
;
YE JIANFEI
;
BAI HONGYU
;
WANG CHANGLI
Author Information
1. 300070天津，天津医科大学研究生院
2. 300280天津，天津大港油田总医院胸外科
- Keywords:
Cetuximab;
Celecoxib;
Cell apoptosis;
KDR;
AQP1
- From:
Chinese Journal of Lung Cancer
2013;(12):625-631
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Neoadjuvant chemotherapy is a new development in the treatment of lung cancer. In recent years, cetuximab and celecoxib have been commonly used in this procedure. This study aims to explore the effect of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer A549 cells. Method The cells were cultured in RPMI-1640 and then divided into four groups: control group, 1 nmol/L cetuximab group, 25 μmol/ L celecoxib group, and 1 nmol/L cetuximab+25 μmol/L celecoxib group. The treatment time was 48 h. The mRNA and protein expression levels of KDR and AQP1 were detected by RT-PCR and Western blot, respectively. The apoptosis, proliferation, and invasive ability of A549 cells before and after transfection were examined using flow cytometry, MTT, and transwell methods. Results Cetuximab and celecoxib inhibited the growth of A549 cells in a dose-dependent manner. Their combination produced a greater growth inhibition than when either was used alone (P<0.01). Cetuximab and celecoxib both induced the apoptosis of A549 cells, and their combination produced a higher apoptosis rate (P<0.01). Cetuximab in combination with celecoxib also induced G1 phase arrest and downregulated the expression of KDR and AQP1 in A549 cells (P<0.05). As a result, the invasion ability of the A549 cells was significantly decreased. Conclusion Cetuximab in combination with celecoxib can synergistically inhibit the growth of A549 cells and downregulate the expression of KDR and AQP1 in A549 cells. The combination of cetuximab and celecoxib is a potential strategy for lung cancer therapy.
